Ilya B. Tsyrlov, MD, has completed his PhD in Biochemistry at the age of 27 and thereafter – a DSci in Molecular Toxicology. He has been working as Group leader, Head of the laboratory, Department chair at Russian Academy of Science. In the United States, served as a Senior Scientist at NCI, NIH, and Professor at Mount Sinai School of Medicine. Since 2005, a president/CSO of XENOTOX Inc, USA. Incepted and developed the Xenobiotical Virology as an interdisciplinary biomedical field. He is the author of 4 monographs and 250+ peer reviewed publications, and has been serving as an editorial board member of reputed Journals.

Biochemistry & Virology

I started my research work for the completion of my doctorate, with diseases of recent knowledge (mid-last century), "Mitochondrial Diseases", considered metabolic and that enter the area of my specialty Endocrinology and now geneticist. They have a syndromic and non-syndromic presentation, affect the devices, organs and systems that most require ATP; so that to address them, began with syndrome, symptoms and possible signs of seeking mitochondrial etiology: Neurosensory Deafness Ototoxicity. Obtaining the Doctorate, I was co-Director of the doctoral thesis of the Physician, Jorge Alejandro Ramos Vila with the syndrome External-Ophthalmoplegía Progressive (mitochondrial disease) and intergenomic nuclear-mitochondrial relationship, syndromic presentation. Later, I was a Research Advisor in the Thesis of the now Dr. in Medicine and Surgery, Raúl Vicente Boudet, relating mitochondrial haplogroups and immunological disease. In this last item, I am also responsible for the studies that relate mitochondrial haplogroups to Chagas disease, to know their influence on the different clinical presentation of this pathology. In the Cathedra of Biochemistry and Molecular Biology FCM - UNC, I have my Clinical Research Office, to perform the Clinical History and Informed Consent, to study patients. Being pathologies of syndromic presentation, we carried out Inter and Multidisciplinary interconsultations (data that we are very valuable).

Endocrinology – Genetics

I am an experienced Researcher Assistant of Medical Microbiology and Immunology and Infection Control Practitioner undertaking scientific research into microorganisms with the aim of identifying new ways of diagnosing, treating and preventing infectious diseases at Theodor Bilharz Research Institute, Egypt. I am skilled and interested in Anti-microbial resistance, Molecular and Immunological diagnosis of infectious diseases, Academic Teaching and Research, Patient Safety and Healthcare Quality. I am a member in the Presidential Leadership Program, a project under patronage of the Presidency of Arab Republic of Egypt to create an enlightened capable caliber of young leaders, with strong skills in blend of Social Science, Governance, Public Administration, Entrepreneurship, Politics and National Security. I have been honored by the award of Best Speech at the 5th International Scientific Conference held in Yerevan State University, Armenia 2018. My goal is to expand my expert horizon in skills of scientific integrity and to gain more scientific experience through working in projects characterized by challenging new ideas and the need for leadership skills.

Medical Microbiology, Immunology and Infection Control

Priya, a synthetic biologist and biochemist by training, is developing high throughput assay platforms at Arbor. Prior to joining Arbor, Priya did her post-doctoral work at MIT, where her work was focused on phage engineering and building phagemid based synthetic biology tool kits for pathway engineering and recombinase based state machines. She obtained her Ph.D. in Pharmacognosy and Biotechnology from University of Illinois at Chicago (UIC) where she studied the mechanism of antibiotic dependent arrest of protein synthesis to understand the action of antibiotics and antibiotic resistance at a molecular level enabling discovery of novel antibiotics. She received her B. Tech in Industrial Biotechnology from Anna University, India and is a recipient of the Khorana Fellowship in 2009.

Pharmacognosy and Biotechnology

Dr. Joshi is an adjunct professor at the A.J. Drexel Plasma Institute, as well as Drexel's School of Biomedical Engineering. He has a special interest in emerging bacterial infections, disinfection and sterilization, and biodefense. Since 1987, Dr. Joshi has taught undergraduate, postgraduate and doctoral students and trained doctoral and postdoctoral fellows in research. He has been mentoring graduates and medical students, who now have successful careers in medicine, academia and the pharmaceutical industry. Since 2004, he has been a member of international mentoring program and minority mentoring program of American Society of Microbiology (ASM), and Infectious Disease Society of America (IDSA).

Bacterial pathogenesis and biofilms; wound infection and healing

I am the lead pathologists’ assistant (PA) certified by the American Society for Clinical Pathology (ASCP) with a master of health science degree appointed for 9 years as an instructor at Baylor College of Medicine (BCM) and a clinical adjunct professor of Quinnipiac University’s Pathologists’ Assistant Program. My clinical work includes recognizing and sampling macroscopic disease within surgical pathology specimens postoperatively or during surgical intraoperative consultation at Ben Taub General Hospital. Occasionally, I cover St. Joseph Medical Center and BCM’s West Belfort lab in this capacity. With optimal patient care as my goal, I decrease the workload of the pathologists and residents who I simultaneously teach by leading through example. After observing and assessing various pathology trainees, including fellows, pathologists’ assistant students, medical students and shadowing undergraduates, I developed a passion to strengthen both pathology residency and pathologists’ assistant programs which is reflected in my curriculum development efforts. For example, by request of the residents, I conduct monthly Interesting Gross Case Workshops currently teleconferenced at a national level to two PA programs. I received Spring 2016’s Fulbright and Jaworski Faculty Excellence Award in Teaching Evaluation verifying the quality and quantity of my educational efforts. Because literature and statistics expose gaps in pathology residency education and dwindling interest to enter the pathology field by medical students, I created and directed the 2017 All-City Anatomic Pathology Symposium sponsored by BCM, which introduced the field of pathology to medical students and undergraduates and offered recapitulation to residents and fellows and ASCP CMLE credits to PAs. The symposium fostered citywide collaborative teaching platforms for pathologists and PAs. The planning committee was comprised of academic PAs-members of the local PA professional organization, Pathassist of Texas in Houston, LLC, founded and presided by myself. While planning this academic feat, American Association of Pathologists’ Assistants offered me speaking engagements for 2 consecutive years and requested my help to incorporate academic PA education into their educational plan. My suggestions produced roundtable discussion groups/workshops for 2 annual conferences. While revolutionizing the PA field as a respected and recognized academic resource for pathology learners, as an example to my colleagues, I strengthened my faculty portfolio by expanding my research and scholarly efforts, an area of weakness for PAs. I designed five research projects with 4 receiving IRB approval. I serve as a first author on four manuscripts with one accepted and one published. In addition, I am a PI for Baylor College of Medicine Tissue Resource, TCGA Tissue Source Repository Tissue Source Site for Clinical and Proteomic Tumor Analysis Consortium (CPTAC) Phase III funded by National Institute of Health, Genome Research Institute and National Cancer Institute. To further implement changes in pathology education, I am a resident in the 6th cohort for the University of Houston’s Executive Doctorate in Professional Leadership Program (EdD) which focuses upon educational needs in medicine and problem-solving strategies through intensive research, thus continuing BCM’s mission of improving health through science, innovation, teamwork and excellence.

Pathology

Reza Nassiri is an Associate Dean of Global Health, Director of Institute of International Health, Professor of Clinical Pharmacology, Professor of Family and Community Medicine and Lecturer in Global Health, Infectious Diseases and Tropical Medicine at Michigan State University College of Osteopathic Medicine. His research interests focuses on Clinical Pharmacology of HIV/AIDS & TB, prevention and control of infectious diseases, neglected tropical diseases, community health, global health and socio-ethical determinants of health. He works on international public health issues and has expertise in global health education, research, policy and governance. He has made contributions in various fields of medical sciences including clinical investigation and health education. On the basis of his extensive experience and expertise in HIV/AIDS and TB, he developed Clinical Research Programs in Brazil, South Africa, Haiti, Dominican Republic and Mexico

Virology, Infectious Disease

Mario A Bianchet received his Ph.D. from The University of La Plata, Argentine, and performed Postdoctoral studies at Johns Hopkins School of Medicine, where he is now an Assistant Professor of Neurology since 2011. He has published 70 papers in reputed journals. As structural enzymologist and expert in ligand recognition, he has participated in several seminal structural and mechanistic studies of macromolecules and ligand/macromolecule interactions of biomedical interest. He has significant contributions to different fields, including bioenergetics: F1-ATPase, xenobiotic-response: NADPH:Quinone oxidoreductases, DNA-repair: Uracyl-Glycosylase/inhibitors, carbohydrate-recognition: animal lectins, and late-stage cell-wall biosynthesis: LD-transpeptidases and their complexes with substrates and carbapenems.

My research aims to understand essential relations between macromolecules’ structure and their mechanisms of action in biological processes involved in human diseases. With that goal I am applying diverse techniques and methods including x-ray scattering and diffraction, as well as computer modeling and simulation to elucidate these relations that will have a direct impact on the understanding, diagnosis, treatment and prevention of human diseases

John J.S. Cadwell received his degree in pharmacology from the University of Miami in 1981. He spent additional time studying at the University of Nottingham and the National Institute of Medical Research at Mill Hill, outside of London. He served in various capacities in the biomedical research fields until 2000 when he was founder of FiberCell Systems Inc. a company specializing in the research and supply of hollow fiber bioreactors. He has over 10 publications in the field and three patents relating to hollow fiber systems and is considered a world expert in the field.

Cell culture technology, stem cells, numismatics, oenophilia, cerevisaphilia, rock art posters, gratefuldeadophilia.

He is a member of the executive board and treasurer of the German Society of Infectious Diseases in 1989 and later on became the President of the German Society for Infectious Diseases from 1997-2001. He worked as Secretary General of the National Congress of Infectious Diseases and Tropical Medicine and became President of the National Congress of Infectious Diseases and Tropical Medicine from 1999 to 2001. He is the Head of the Department of Internal Medicine at the Klinikum St. Georg gGmbH Leipzig Department of Infectious Diseases and Tropical Medicine and Nephrology, Teaching Hospital at the University of Leipzig.

Infectious diseases, antibiotics, viral hepatitis, Influenza, gastrointestinal infections, HIV/AIDS, pneumonia, nosocomial infections

Prof. Chmielewski received MSc from Warsaw University of Technology (1965), PhD from Institute of Organic Chemistry (1972), and habilitation (1981). He was Research Director of the Institute and then Director. He spent two research stays, in Purdue University and in Southern Illinois University in Carbondale. He was a visiting professor in Purdue University and University of Sevilla. He was a JSPS fellow, and a fellow of the Royal Society of Chemistry Journals Grant for visitors. He was Vice-President of the Polish Academy Sciences for the term 2011 – 2014.

The research interest includes stereocontrolled syntheses of β-lactam antibiotics. Particularly using the [2+2]cycloaddition of isocyanates to vinyl ethers, 1,3-dipolar cycloaddition of nitrones, and application of the copper catalyzed cycloaddition of nitrones to terminal acetylenes. The other projects involve also the synthesis of amino- and iminosugars from unsaturated sugar lactones and synthesis of glycosyl hydroperoxides and their use as epoxidation reagents

Byungse Suh has completed his BS in pharmacy from Chungang University, Seoul, Korea; PhD at the age of 28 from University of Kansas; postdoctoral studies from University of Iowa; and MD from University of Miami. He has completed the residency and fellowship from University of Wisconsin Hospital. He is Professor of Medicine and published more than 110 papers.

Pharmacokinetics of antimicrobial agents Drug protein binding in disease states In vitro determination of drug phototoxicity Clinical trial studies of antimicrobial agents

John J S Cadwell received his degree in Pharmacology from the University of Miami in 1981. Since that time he served in various sales, marketing and business development capacities until founding FiberCell System in 2000. As president and CEO he has filed and been issued three patents in the field of hollow fiber bioreactors and authored many publications in the field

Cell culture technology, stem cells, numismatics, oenophilia, cerevisaphilia, rock art posters, gratefuldeadophilia.

Mario A Bianchet has completed his PhD from The University of La Plata, Argentine, and performed Postdoctoral studies at Johns Hopkins University School of Medicine, where he is now a Assistant Professor of Neurology since 2011. He has published 65 papers in reputed journals. As structural enzymologist and expert in ligand recognition, he has participated in several seminal structural and mechanistic studies of macromolecules and ligand/macromolecule interactions of biomedical interest. He has important contributions to different fields, including bioenergetics: F1-ATPase, xenobiotic-response: NADPH:Quinone oxidoreductases, DNA-repair: Uracyl-Glycosylase/inhibitors, carbohydrate-recognition: animal lectins, and late stage cell-wall biosynthesis: LD-transpeptidases and their complexes with substrates and carbapenems.

My research aims to understand essential relations between macromolecules’ structure and their mechanisms of action in biological processes involved in human diseases. With that goal I am applying diverse techniques and methods including x-ray scattering and diffraction, as well as computer modeling and simulation to elucidate these relations that will have a direct impact on the understanding, diagnosis, treatment and prevention of human diseases

Martin qualified in medicine from Newcastle University in 1982 and has worked as a GP since 1986. He obtained a Masters qualification in public health at Cambridge University in 1997. He has had a longstanding interest in applying evidence-based medicine to prescribing and therapeutics. He has previously worked for the National Prescribing Centre and the Department of Medicines Management at Keele University. From 1999 he has worked as a part-time GP in Conwy, North Wales, and initially worked as Medical Director for Conwy Local Health Board. Following the reorganisation of health services in Wales in 2009 he became Deputy then Acting Medical Director for the Health Board which manages all primary and secondary care NHS services in North Wales. He helped to organise and run the Diploma in Therapeutics at Cardiff University between 2005 and 2010. He chaired the New Medicines Group for Wales from inauguration in 2007 through to 2010. He is a Clinical Adviser on prescribing and evidence-based medicine for the Royal College of GPs, and is member of one of NICE’s technology appraisal committees.

He has had a longstanding interest in applying evidence-based medicine to prescribing and therapeutics.

Prof Samir Kumar-Singh is a certified medical doctor with a doctorate in Pathology and a Master degree in Laboratory Animals. He is a full-time research professor of Molecular Pathology at the Faculty of Medicine, University of Antwerp, Belgium and is affiliated to the Vaccine and Infectious Disease Institute, Belgium. He has published a well-cited body of work on molecular pathology of cancer and neurodegeneration involving patient studies and mouse modelling. Professor Kumar-Singh serves on several review and editorial boards and international consortia. Since 2012, his group is engaged in studying the pathomechanism of hospital acquired pneumonia especially ventilator-associated pneumonia (VAP) and has developed several authentic rat and mouse VAP as well as acute and chronic pneumonia models to study disease pathogenesis and for biomarker discovery as well as high-throughput in vitro screens for new antimicrobial targets.

Biomarker discovery, New antimicrobial targets

Anna Malm has completed her PhD in 1989 from Medical University in Lublin, Poland. She is the head of Department of Pharmaceutical Microbiology in Medical University in Lublin. She works at full professor position. She is a specialist in medical microbiology. She has published more than 200 papers mainly in reputed journals in the field of medical microbiology, including studies on antibacterial/antifungal activity in vitro of the compounds of plant or synthetic origin.

Pharmaceutical Microbiology

Bing Xie has completed his PhD at the age of 30 years from East China University and postdoctoral studies from the University Hongkong, Department of Ecology Diversity. He is the vice director of Department of Environmental Science & Technology of East China Normal University. He has published more than 100 papers in reputed journals and has been serving as an editorial board member of international journal.

The research program focuses on the use of ecological and engineered biological systems for environmental pollution control, bioremediation, and the treatment of wastewater from industrial.

Dr. Ananda M. Chakrabarty serves as Senior Science Advisor of Amrita Therapeutics Limited. Dr. Chakrabarty is a Amrita’s Senior Science Mentor and Global Domain Expert relating to how bacterial proteins effectively combat cancers, parasites, and viruses in the human body. Dr. Chakrabarty serves as a Distinguished University Professor of Microbiology and Immunology at the University of Illinois College of Medicine, and advises senior officials in the U.S. and abroad on policies relating to biotechnology and related technology transfer. He is a Consultant to the United Nations. In 1980, Dr. Chakrabarty’s genetically modified Pseudomonas bacteria became the first genetically-engineered organism to gain a patent, as a result of the Supreme Court decision in Diamond vs. Chakrabarty. Dr. Chakrabarty undertook pioneering biotechnology research into the therapeutic potential for protein products of bacteria, both at the University of Illinois at Chicago (UIC) and on behalf of CDG Therapeutics, a U.S. biotechnology start-up company engaged in clinical cancer research. Dr. Chakrabarty has led path-breaking research into the therapeutic qualities of protein products of bacteria. His work includes recent studies with water-soluble products of pathogenic bacteria demonstrating significant promise for cancer therapies, effective against HIV/AIDS, malaria and perhaps even tuberculosis. Dr. Chakrabarty was a part of the Advisory Committee that resulted in creation of the International Center for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy and rejoined the ICGEB Advisory Board. Dr. Chakrabarty has numerous publications and has received many notable awards for his contributions to biotechnology, including Padma Shri in 2007, one of the Indian Government’s highest civilian honors.

Cell Biology, Microbiology, Pseudomonas aeruginosa, Cancer Cells, Biotechnology, Oncology, Cancer Biology, Cancer Therapy, Pseudomonas, Malaria, Cystic Fibrosis, Genetic Engineering, Infectious Diseases, Cancer Chemotherapy, Mutation

Akira Kaji is a professor of microbiology, School of Medicine, University of Pennsylvania. He contributed to the deciphering of genetic code by his discovery of the fact that the complex of poly-U with ribosome binds specifically tRNA specific for phenylalanine. He also discovered RRF.

The following is a short review of Akira Kaji past work. In 1963, they discovered that specific tRNA binds to the complex of mRNA and ribosome. This finding was essential to decipher the genetic code (9). Regarding RRF, upon in vivo inactivation of RRF, the ribosome starts the unscheduled translation downstream from the termination codon. Crystal structure by X-ray crystallography as well as solution structure by NMR has revealed that RRF is a near perfect structural mimic of tRNA. Indeed, we found that RRF functionally mimics tRNA in that it moves in the inter-subunits space like tRNA does. However, the mode of RRF binding to the ribosome is different from that of tRNA. We also discovered arginyl-tRNA protein transferase in 1963(10). This enzyme is an essential for higher eukaryotes and involved in post-translational protein modification.

2006-present: Adjunct Professor of Biochemistry & Molecular Biology, Indiana University School of Medicine 1996-present: Director, WM Keck Center for Transgene Research, University of Notre Dame 1983-present: Kleiderer/Pezold Professor of Biochemistry, University of Notre Dame 1979-2002: Dean, College of Science, University of Notre Dame 1977-1983: Professor, University of Notre Dame 1974-1977: Associate Professor, University of Notre Dame 1970-1974: Assistant Professor, University of Notre Dame 1968-1970: NIH Postdoctoral Fellow, Duke University 1968: Ph.D. in Biochemistry, University of Iowa 1964: B.S. University of Scranton

The interests of Professor Castellino\'s laboratory involve the structure, function and activation of proteins that participate in blood coagulation and blood clot dissolution. The in vivo mechanisms of the roles of these proteins in these processes are being addressed through in vivo targeted gene-replacement approaches and corresponding in vitro structure-function studies on these genes and proteins are being studied by the most modern biophysical techniques, e.g., X-ray crystallography, NMR, etc. Most of these proteins exist in an inactive state in plasma and thus must be activated to enzymes to exhibit their functional properties. The molecular events involved in the activation and analysis of the concomitant structural changes that occur in the protein are investigated by modern biochemical techniques. Major tools of the laboratory involve cloning, mutagenesis and expression of variant recombinant proteins and individual protein domains, immunochemical studies of the proteins, as well as physical and chemical analysis of their solution structures. The properties of the proteins are then related to their functions. Another project receiving attention involves the structure-function relationships of small gamma-carboxyglutamic acid (Gla)-containing peptides from marine cone snails that target the brain NMDA receptor. These peptides inhibit the flow of calcium into neuronal cells, this latter event being responsible for the neuropathology associated with stroke, epilepsy, Alzheimer\'s Disease, ALS, etc. The biochemical, pharmacological and neurobiological mechanisms of the actions of these peptides are under study. Peptide synthesis, receptor binding, molecular biological and electrophysiological tools are currently employed in this work. To determine the biological functions of genes encoding coagulation and clot-dissolving proteins in hemostasis, cancer, inflammation, wound healing, embryonic implantation and development, metastases, and athersclerosis, gene deletion and other gene targeting experiments are being performed in mice, in conjunction with phenotyping of these animals. Such studies are expected to provide important information on the development and progression of these disease states.

Professor George L. Mendz has an MSc from the University of Barcelona (Spain), and a PhD from the University of NSW. He has been Lecturer at the College of Natural Sciences, the University of Puerto Rico (San Juan); Research Associate at the School of Chemistry and the Department of Biochemistry, the University of Sydney; ARC Senior Research Fellow and Associate Professor at the School of Biochemistry and Molecular Genetics, the University of NSW; Associate Professor at the Department of Bacteriology, the University of Bordeaux II; and Associate Professor at the School of Medical Sciences, the University of NSW.

More recently, he had acquired expertise in global analyses involving proteomics and transcriptomics by investigating microorganism responses to stress, as well as in bacterial genome sequencing and the application of metagenomics to characterise bacterial populations.

Dr. Kei Amemiya is a Principal Investigator in the Bacteriology Division at the US Army Medical Reseach Institute of Infectious Diseases. He has been at USAMRIID since 1999 and has been involved in developing vaccine candidates against plague, glanders, and melioidosis. His interest has been in studying the host’s immune response to the pathogen and vaccines in small and large animal models. Before coming to USAMRIID, he was at the National Institutes of Health and Georgetown University, where he was studying the host response to bacterial and viral pathogens or autoimmune diseases in humans.

Molecular Biology, Immunology, Microbiology, Infectious Diseases

Dr. Joshi is director of surgical site infections and bacterial pathogenesis. He is an assistant professor in the Departments of Microbiology & Immunology and Surgery, and an adjunct professor at the A.J. Drexel Plasma Institute, as well as Drexel's School of Biomedical Engineering. He has a special interest in emerging bacterial infections, disinfection and sterilization, and biodefense. Since 1987, Dr. Joshi has taught undergraduate, postgraduate and doctoral students and trained doctoral and postdoctoral fellows in research. He has been mentoring graduates and medical students, who now have successful careers in medicine, academia and the pharmaceutical industry. Since 2004, he has been a member of international mentoring program and minority mentoring program of American Society of Microbiology (ASM), and Infectious Disease Society of America (IDSA).

Medical microbiology, pathology, parasitology, communicable diseases, hospital-acquired infections and infection control methods

Awards RESEARCH & SCHOLARSHIP AWARDS 2015 Fellow of the American Academy of Microbiology 2014 Faculty Excellence Award (one award given per year within the School of Molecular and Cellular Biology at the University of Illinois). 2004 Award for Excellence in Research and Scholarship at the Associate Professor Level - University of Houston (one university award per year at each academic rank). 2002 Award for Excellence in Research and Scholarship at the Assistant Professor Level - University of Houston (one university award per year at each academic rank).  1999 Young Investigator Award, 10th International Meeting Campylobacter & Helicobacter. 1997 Natural Science and Mathematics Alumni Association Award. 1996 Oakridge Junior Faculty Award for Life Sciences Research. 1981 NSF Undergraduate Research Award. TEACHING AWARDS AND RECOGNITION 2010, 2013 Cited as a Teacher ranked as outstanding by their students for Molecular and Cellular Biology/Life Sciences and College of Medicine Courses. 2008, 2009 Cited as a Teacher ranked as excellent by their students for Molecular and 2011, 2012 Cellular Biology/Life Sciences and College of Medicine Courses. 1999 Teaching Excellence Award, College of Natural Sciences and Mathematics. 1998-1999 University of Houston Enron Award for Excellence in Teaching at the University level. RECENT LECTURESHIPS, MEETING CHAIRS, LEADERSHIP POSITIONS 2015 Vice-Chair, Gordon Conference on Chemical & Biological Terrorism Defense, Ventura, CA, March 2015. 2013 Chair, Bacteria-Host Interactions (2013) 2013 International Conference on Bacillus anthracis, B. cereus, and B. thuringiensis, Victoria, Canada, September 2, 2013. 2013-2014 Chair, Division B (Microbial Pathogens) of ASM. 2013 Discussion Leader/Session Chair, Organizing Committee, 2013 Gordon Conference on Chemical & Biological Terrorism Defense, Ventura, CA, March 10-15, 2013. 2012-2013 Chair Elect, Division B (Microbial Pathogens) of ASM, 2012-2013. 2011 Session Chair, Organizing Committee, 2011 International Conference on Campylobacter, Helicobacter, and Related Organisms, Vancouver, British Columbia, Canada, August 28 – September 1, 2011. 2011 Keynote Speaker, 23rd Annual Buffalo Conference on Microbial Pathogenesis – Witebsky Center for Microbial Pathogenesis and Immunology (2011) Of Persistence, Cancer, and Asthma: The Curious Case of Helicobacter pylori, Buffalo, NY, April 29, 2011. 2011 Organizing Committee, and Discussion Leader/Session Chair, 2011 Gordon Conference on Chemical & Biological Terrorism Defense, Ventura, CA, March 20-25, 2011.

Genetics, Host-Pathogen Interactions, Membrane Biology, Microbial Physiology, Molecular Immunology, Receptor Biochemistry, Signal Transduction, Toxins

Dr. Goc obtained her M.S. and Ph.D. from the Jagiellonian University, Cracow, Poland. She conducted her postdoctoral training at Case Western Reserve University, Cleveland, OH, and the University of Georgia, Athens, GA. She also worked as a Research Biologist at the VA Medical Center, Augusta, GA. Currently, as a Head of Infectious Diseases Division at Dr. Rath Research Institute, Santa Clara CA, she leads a Lyme disease project. Dr. Goc has published over 30 peer-reviewed publications, two book chapters, and has presented her research at numerous national and international scientific meetings. She is also an active member on one editorial board and the recipient of several national and international awards.

Molecular biology, biochemistry and cell biology in the fields of microbiology, immunology, cancer, and vascular biology

Lloyd H Kasper, MD, is Professor of Medicine in Neurology, Microbiology, and Immunology at Dartmouth Medical School in Hanover, New Hampshire. After completing medical school at Rush Medical College in Chicago, IL, he finished his post-graduate clinical training in internal medicine, neurology, and microbiology at Dartmouth-Hitchcock Medical Center. In addition to his research responsibilities, he is Co-Director of the Dartmouth-Hitchcock Multiple Sclerosis (MS) Clinic Program in Immunotherapeutics. He is also a member of numerous professional societies including the American Academy of Neurology, American Federation for Clinical Research, and American Society of Microbiology. Dr Kasper has had a longstanding career in researching the immunopathogenesis of MS, and has received a Collaborative MS Research Center Award to lead investigators in determining how T cells fail in people with the disease. He also studies the immunopathology of Toxoplasma infections. His work has been published extensively in peer-reviewed journals including the Journal of Immunology, Journal of Clinical Investigation, and Experimental Parasitology. Dr Kasper is also a reviewer for many scholarly journals including the Journal of Infectious Diseases, Annals of Neurology, and Journal of Neurological Science. His professional activities include serving as Chairman and Co-Chair for several national and international conferences and organizational committees.

Microbiology, Immunology, Neurology

Timms is Professor of Microbiology and Director of Research at QUT’s Institute of Health and Biomedical Innovation in Brisbane Australia. He is a nationally and internationally renowned microbiologist with specific expertise in the area of Chlamydia. His laboratory is acknowledged as the leading Australian laboratory and one of the leading groups internationally working on all aspects of chlamydial infections. Timms has published over 170 refereed journal papers and is editor of the journal, Pathogens and Disease.

He leads a well established research team of 10 people. His research group is developing vaccines and new diagnostics for chlamydial diseases in humans and animals as well as an improved understanding of chlamydial genomics, cell biology and pathogenicity. The group is widely acknowledged for its major contributions to chlamydial infections in koalas and other wildlife, including the development of a vaccine for koalas.

Mohamed K. Fakhr, is currently an Associate Professor of Molecular Microbiology in the Department of Biological Science at the University of Tulsa, USA. After obtaining his Ph.D. from Oklahoma State University in 2002, Dr. Fakhr, moved to North Dakota State University where he worked as a Postdoctoral Research Associate then a Research Assistant Professor at the Department of Veterinary and Microbiological Sciences. In 2008, Dr. Fakhr moved to Tulsa, where he currently runs an active research program in the area of Molecular Typing and Detection of Foodborne Bacterial Pathogens alongside exploring the mechanisms by which these foodborne pathogens develop resistance to antimicrobials.

Microbiology, Biological Science, Veterinary Science

Dr. Ling Zhan is a pediatric dentist who cares for children and adolescents at both the Mission Bay and Parnassus campuses. Her treatment philosophy is very prevention-oriented. She works closely with her patients and their families to identify risk factors for common dental diseases, such as dental caries, and to adopt scientifically-based preventive and treatment regimens to avoid future diseases. Her practice provides routine as well as complex care, including care for children with dental or medical conditions who require treatment under sedation or general anesthesia. She works closely with other dental specialties to treat children with complex dental disease, such as amenogenesis imperfecta. In addition to patient care and education, Zhan conducts clinical and translational research projects that are focused on microbiological aspects of tooth decay; oral prevention programs guided by risk assessment; and identification of protocols to prevent or eliminate dental caries in children. Zhan completed her pediatric dentistry residency training at UCSF. She is a member of the American Academy of Pediatric Dentistry and a diplomate of the American Board of Pediatric Dentistry.

Pediatric Dentistry, microbiological aspects of tooth decay, dental diseases

March 2004: PhD,Microbiology,University of Groningen,The Netherlands. Nov 1989: MCCEE‡,MD Equivalent,Medical Council, Canada. Nov 1982: MBBS, Med degree. Bangladesh.

Microbiology, Infection, Medicine, Emerging Pathogens, Probiotics, Salmonellosis.

Liaqat Ali Chaudhry completed MBBS from King Edward Medical College university Lahore1981. He completed his post-graduation in Diploma in Tuberculosis & Chest Diseases -Punjab University Lahore-Pakistan, MCPS from College of Physicians and Surgeons Pakistan and MRCP, FRCP from The Royal College of Physicians Dublin-Ireland. He worked as house physician, Registrar, Assistant professor at King Edward Medical College Lahore, 1982-1987. Later he joined MOH of Saudi Arabia worked as Specialist Physicians chest specialist on Feb-1988, Consultant Pulmonologist and Chief of Tuberculosis Center, Dept. of Internal Medicine & Chest diseases Dammam medical complex and Honorary Associate & Professor Dammam Medical University, Eastern Province K. Saudi Arabia – 2011 and Chairman Internal Medicine & Consultant Invasive.

Consultant Pulmonologist and Chief of Tuberculosis Center, Deptt.of Internal Medicine & Chest diseases Dammam medical complex and Honorary Associate & Professor Dammam Medical University, Eastern Province K.Saudi Arabia.

Dr. Joshi is completed his MD, and MSc and PhD in medical microbiology. Since year 1987 he is in the field of academics, held positions ranging from lecturer through professor at various institutions. He has research experience from the fields of antimicrobial drugs and resistance mechanisms, bacterial pathogen-host interactions and immune responses, infected wound healing, and biofilms and infection control strategies. His current teaching interest includes bacterial infections, antibacterial agents, and vaccines of biodefense interests. Dr. Joshi is a member of American Society of Microbiology (ASM), Infectious Disease Society of America (IDSA), Surgical Infection Society of North America (SISNA), New York Academy of Sciences (NYAS), and holding life memberships of Indian Association of Medical Microbiologist (IAMM), Indian Association of Pathologist and Microbiologist (IAPM) and Society of Biological Chemistry of India (SBC). He is a proud member of ASM’s International Mentoring Program and Minority Mentoring Program.

Novel Antimicrobial and Antibiofilm strategies, Wound infection and Healing, Biofilms, Mechanisms of Bacterial inactivation and ROS, Acinetobacter baumannii Infection, Carbapenem resistance.

Tadashi Shimamoto has completed his PhD at the age of 28 years from Okayama University, Japan and postdoctoral studies from University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School. He is a professor and a vice dean of Graduate School of Biosphere Science, Hiroshima University. He has published more than 60 papers in reputed journals and has been serving as an editorial board member of Microbiology and Immunology.

Microorganisms that cause food poisoning, such as E. coli O157, Salmonella, Vibrio parahaemolyticus, Campylobacter and norovirus.

John Clerici is a founding Principal of Tiber Creek Partners, LLC and a Partner in the government contracts practice at McKenna Long & Aldridge LLP. For over 13 years, John has been at the forefront in the creation of the public health preparedness sector, including helping large pharmaceutical and emerging biotechnology companies develop creative approaches to access non-dilutive capital to fund the development of biotechnology for emerging disease and engineered threats. Since 1999, John has assisted over three dozen companies in obtaining nearly $4 billion in funding for research, development and procurement of public health countermeasures to the Federal government, including the majority of the awards made under Project Bioshield, the U.S. Government’s initiative for preparing the Nation against a bioterrorist attack. In 2005, John played a substantial role in the drafting and passage of the Public Readiness and Emergency Preparedness Act (PREP Act), landmark legislation that provides substantial liability protections for makers and distributors of pandemic, epidemic, and bioterrorism countermeasures. John testified as an expert in support of this legislation on four occasions before the United States Senate Appropriations Committee, HELP Committee, and Judiciary Committee. In 2006, John was instrumental in the passage of legislation creating the Biomedical Advanced Research and Development Authority (BARDA), which builds upon and improves Project BioShield. John’s expertise in the area of public health preparedness has been recognized by leading news outlets such as the Wall Street Journal, Business Week, the Associated Press, the Boston Globe, and The Hill. He has also appeared live on the Fox News Channel as a bioterrorism expert. Prior to joining the firm, John was a judge advocate with the U.S. Air Force where, among other assignments, he advised the Air Force Research Laboratory on the procurement of technology from research institutions throughout the United States, Europe and Asia. John has appeared as a military law analyst for the Fox News Channel and MSNBC before national audiences. John earned his Juris Doctor from the University of North Carolina at Chapel Hill. He did his undergraduate work at the Catholic University of America, graduating summa cum laude.

Public health Pharmaceutical and emerging biotechnology

Glenn is a Senior Partner at TranScrip Partners USA. He is trained in medical microbiology and infectious diseases and has over 25 years of pharmaceutical industry experience in various areas including clinical research, commercialization, scientific communications including publication planning, strategic drug development, life cycle management and global launch programs. Glenn has been instrumental in the development of ciprofloxacin and moxifloxacin as well as other drugs in the Bayer portfolio for whom he worked for 15 years. After leaving Bayer he worked as a consultant microbiologist and later joined Oscient, during which time he was involved in the commercialization and launch of gemifloxacin (Factive) in the US as well as co-marketing and business development deals globally. In 2006 he joined Replidyne as Executive Director of Scientific Affairs and worked on the company’s anti-infective portfolio, including faropenem. In 2008 Glenn became the Head of Medical Affairs at ViroPharma where he oversaw educational, publication and other related activities for Vancocin, maribavir and Cinryze. He later worked for Optimer Pharmaceuticals as Senior Vice President of Medical Affairs and built a team to support the launch of fidaxomicin (Dificid) which has been one of the most successful antibiotic launches ever. Glenn is a member of the Scientific Steering Committee for the GTCBio Annual Summit on Anti-infective Partnering as well as the Anaerobe Society. He is also Chair of the ACCP Chest Infection Network and a member of the ACCP Executive Council of Networks. In 2009 Glenn was honored by the American College of Chest Physicians with the Alfred Soffer Award for contributions to the College. He has published over 140 peer-reviewed manuscripts, presented >270 scientific posters, wrote 5 book chapters and is editing a upcoming e-book on Clostridium difficile. Glenn is on several journal Editorial Advisory Boards including the Lancet Infectious Disease and F1000.

strategic drug development life cycle management

Noreddin received his Phd in University of the Pacific and research training at the Department of Medicine, Stanford University, CA. He had postdoctoral fellowship, University of Manitoba followed by an American College of Clinical Pharmacy fellowship. His research interest includes Pharmacokinetic/Pharmacodynamic modeling of anti-infective therapy, clinical simulation and bacterial resistance in biofilm studies. He has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions.

Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy Clinical simulation and Monte Carlo analysis
Bacterial resistance in biofilm studies
Cancer epigenetic studies
Minority health care studies

Professor Thomas is presently Director of the Biofilm Research Laboratory for Translational Studies in Medicine, Dentistry, and Industry at West Virginia University, Morgantown, WV, US and Senior Consultant to Clinical Microbiology , WVUH. He created the International Tri-University Biofilm Research Consortium in 2002 to further global investigations and education,initially focusing on VAP and the MV ICU patient highlighting the oral -systemic link. He completed a six month Sabbatical at Cardiff University, School of Dental Medicine in 2008 and has travelled extensively, lecturing in 16 countries, 4 continents and to greater than 15,000 educators and public healthcare providers. He is co-organizer of the First Asia Pacific Biofilm Congress which is to be held in China, Spring 2011. He has published extensively on diverse microbial topics emphasizing oral biofilms and their importance in probiotic management, and their link to systemic diseases , chronic wounds, global antibiotic resistance and recently the tumor –biofilm connection.

Biofilms and Chronic Diseases

The Alliance for the Prudent Use of Antibiotics (APUA) is pleased to present the 2012 APUA Leadership Award to Professor Roman S. Kozlov and APUA-Russia for sustained leadership to contain antibiotic resistance in Russia and the adjacent region. This award also recognizes the Chapter‟s collaborative efforts with the Inter-Regional Association for Clinical Microbiology & Antimicrobial Chemotherapy (IACMAC) and the Institute of Antimicrobial Chemotherapy (IAC) of Smolensk State Medical Academy (SSMA). As President of APUA-Russia, Professor Kozlov has led the remarkable efforts of this chapter to promote the prudent use of antibiotics. APUA-Russia has been extensively involved in activities throughout Russia, Belarus, Ukraine, and other countries of the Former Soviet Union for the establishment of a network of sentinel laboratories and organization of continuous surveillance programs of both community and hospital-acquired pathogens. APUA-Russia is based at SSMA in Smolensk, where Professor Kozlov serves as IAC Director. Collaboration with the IAC has provided the laboratory facilities to develop the surveillance work. The results of these studies have been used as a basis for development of national guidelines on the management of community-acquired pneumonia, hospital-acquired pneumonia, intra-abdominal infections, and skin and soft-tissue infections.

Antimicrobial Chemotherapy

Dr. Ahmed Lasfar is a Researcher working on improving the use of Interferon in cancer and determining the mechanisms of resistance to interferon therapy at the University Hospital Cancer Center New Jersey Medical School/University of Medicine and Dentistry of New Jersey. He is a member of the Department of Biochemistry and Molecular Biology at NJMS/UMDNJ. He has completed his Post Doctoral training 1999-2002 in the Department of Molecular Genetics Microbiology and Immunology at Robert Wood Johnson Medical School UMDNJ under the supervision of Dr. Sidney Pestka Leader for the approval of IFN use in Clinic by the FDA in 1986 and the winner of the National Medal of Technology in 2002. Dr. Ahmed lasfar has received a PhD in Immunology from Paris University of Science France in 1996. He has completed his Master Degree in Rene Descartes University School of Medicine France 1992. He received several awards including two excellence scientific awards from the New Jersey Commission on Cancer Research and one award from the International Society for Interferon and Cytokine Research.

Interferon lambda signaling in normal and cancer cells
Strategies for the improvement of interferon treatment in melanoma
Role of Interferon lambdas in Hepatocelluar Carcinoma
Mechanisms of TGF beta resistance

Bernd Rehm is a department head of microbiology in Massey University

Microbial biosynthesis of polymers and biosurfactants

Earned MD degree in 1978 from Carol Davila School of Medicine, Bucharest, Romania. Started the medical career in 1978 in the Clinical Laboratory at the Municipal Hospital, Bucharest in 1985, did the first postdoctoral training in Immunology and Immunochemistry Department, University of Manitoba, Winnipeg, Canada in 1991 came to New York City at Mount Sinai School of Medicine for 4 years in a second postdoctoral training in cellular and molecular immunology in the Department of Microbiology in 1995, promoted to the rank of Assistant Professor, and in 1998 to the rank of Associate Professor in the Department of Microbiology, Mt. Sinai School of Medicine, New York in 2004, joined the Uniformed Services University of Health Sciences in Bethesda, MD. as Associate Professor of Medicine, Division of Immunology, and in 2008 has been promoted to the rank of Professor with tenure where he currently performs basic and clinical research projects.

pathology

Akira Kaji has completed his Ph.D in 1958 at The Johns Hopkins University and did postdoctoral studies from various places including the Rockefeller Institute in New York. He is a professor of Microbiology at Univ. of Pennsylvania. He has published more than 200 papers in reputed journals.

Protein synthesis

Verma is Chief of the Epidemiology and Genomics Research Programs (EGRP) Methods and Technologies Branch (MTB), and oversees its research portfolio and initiatives that focus on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility. He is responsible for stimulating EGRP-funded research on epigenetic approaches in cancer epidemiology and has been instrumental in developing epigenetics research for NIH as a whole. Dr. Verma helped to develop a Request for Applications (RFA) on Environmental Influences on Epigenetics with the National Institute of Environmental Health Sciences (NIEHS) and represents the Division of Cancer Control and Population Sciences (DCCPS), in NIHs Roadmap Initiative on EpigeneticsExternal Web Site Policy. He helped develop an RFA on Comparative Systems Genetics of Cancer with NCIs Division of Cancer Biology (DCB), and is known within the extramural research community as an EGRP Program Director for Program Announcements (PAs) on Small Grants for Cancer Epidemiology and Pilot Studies in Pancreatic Cancer. He also organized a workshop to explore developing a concept for a research initiative on mitochondrial DNA and cancer epidemiology. Dr. Verma was, and continues to be, a co-Program Director for initiatives in gene-environment interactions in cancer etiology, including the Breast and Prostate Cancer and Hormone-Related Variants Cohort Consortium (BPC3), which is a collaborative project to pool data and biospecimens from a group of large prospective cancer epidemiology cohorts. Dr. Verma joined EGRP as a Program Director in 2004. In 2005, he was appointed Acting Chief of EGRP\\\'s former Analytic Epidemiology Research Branch (AERB). When EGRP reorganized in 2007, he was appointed Acting Chief of MTB and of the Host Susceptibility Factors Branch (HSFB), for which he served as Acting Chief through 2008. Before joining EGRP, he was a Program Director in NCI\\\'s Division of Cancer Prevention (DCP), where he worked in the areas of biomarkers, early detection, risk assessment, and prevention. He also was Coordinator of DCP\\\'s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. He was on the faculty in the Biochemistry Department of Georgetown University before joining NIH.

Biomarkers, epigenetics, epidemiology technologies, proteomics, microRNA, methylation, mitochondria, nanotechnology, risk assessment, susceptibility factors, and systems genetics

Powell received his Ph. D. in Biochemistry from The University of California at Davis with postdoctoral training at The National Cancer Institute in Frederick Cancer and The University of Tokyo Medical Institute. He spearheaded and managed a bioproduction and bioanalysis research services capability for the DoD, and received federal recognition for helping to transition candidate biodefense vaccine products into advanced development. He is an adjunct professor at Johns Hopkins University where he teaches a medical microbiology course on bacterial pathogens, and has certificates in Regulatory Compliance and Project Management. Founder and President of Cernomics Solutions, he now provides consultation services to pharmaceutical, biotechnology and biodefense clients. Dr. Powell has more than 47 scientific publications, two patents, and serves journal peer review, biological standards development, and other aid to knowledge discovery and medical product development.

Bacteriology
Systems Biology
Medical Sciences
Proteomics
Molecular Biology
Microbiology
Biotechnology
Immunology
Biodefense and Pharmaceutical Technology

Menachem Shoham completed his Ph.D in the Weizmann Institute of Science (isreal) and he is currently working in the Case Western Reserve University as an associate professor in the department of Molecular Biophysics and Biochemistry and his main research in the laboratory focuses on drug discovery and drug screening to combat infectious diseases. Shoham received many positions and honors and successfully published 57 peer reviewed publications in his research.

Drug screening to combat infectious diseases

Valyi-Nagy received medical and research training in Hungary and at the University of Texas, the Wistar Institute of Philadelphia and Vanderbilt University in the United States. He has been on the faculty of the University of Illinois at Chicago since 2002 where currently he is Associate Professor and Director of Neuropathology. In his research, he is primarily interested in mechanisms by which herpes simplex virus (HSV) causes nervous system injury during natural infections and by which HSV destroys tumor cells during oncolytic therapy.

Nervous system infections, herpes simplex virus pathogenesis, mechanisms of virus induced neurodegeneration, viral oncolytic therapy.Microbiology and Biotechnology, Bioresource Technology, Biotechnology Progress, Carbohydrate Polymers, Chemical Engineering Science, Colloids and Surfaces B Biointerfaces, Desalination Environmental Progress, Environmental Technology,Industrial and Engineering Chemistry Research.

Peter Panizzi, Ph.D. is an Assistant Professor at Auburn University. He received his doctorate from Vanderbilt University in 2004 and completed post-doctoral fellowship at the Center for Systems Biology at the Massachusetts General Hospital from 2007-2010. He has co-authored >32 high-impact articles and was awarded a NIH pathway to Independence Grant (K99R00) from NHLBI before coming to Auburn. His research focus is to better understand how certain bacteria are able to cause human disease and in turn use this knowledge against the microbe to detect specific sites of infections and identify casual pathogen.

Bacterial pathobiology, biochemistry and molecular imaging

Foodborne Bacterial Infections and Safety

B. Y. Chin attended the United World College of South East Asia Singapore and Lawrence Academy in Groton Massachusetts high school Mount Holyoke College in South Hadley MA, BA Biological Sciences, The Johns Hopkins University ScM Physiology and PhD Toxicological Sciences. She spent her postdoctoral fellowship in Molecular Toxicology at US Department of Energy at Pacific Northwest National Laboratory in Richland WA. Currently she is at Beth Israel Deaconess Medical Center/Harvard School of Medicine in Boston MA in the Department of Surgery B. Y. Chin is also a member of the Teaching Faculty of the 1st year medical curriculum Anatomy Histology and Physiology at Harvard Medical School. She has published over 30 peer review articles and serves on the Editorial Board of World Journal of Pharmacology and as a guest editor in Current Chemical Biology.

His research interests lie in environmental pollutants, airborne particulate matter, ozone and carbon monoxide. However, since arriving at Beth Israel, he is active in propelling and challenging the paradoxical use of low dose carbon monoxide (CO). CO, once viewed and stigmatized as a toxic molecule, has now emerged in the last 10 years with potential therapeutic applications; its pleiotropic effects encompass roles ranging from that of an immunosuppressive agent to that of a host defense molecule. His current research is focused on elucidating the mechanism whereby exogenous administration of CO protects against a murine model of sepsis; most notably that induced by Enterococci faecalis.

Biochemistry

Abu Salim Mustafa PhD (1979) and FRCPath (1998) and Full Professor (since 1996) at the Faculty of Medicine, Kuwait University, Kuwait. Visiting Professor (Resource Person Program) of American Society for Microbiology/ UNESCO in 2001 and 2004. Administrative Experience at Kuwait University: Research Coordinator in 1992, Graduate Program Director in 1998, Member of Medical Research Council in 2001 and Director of Research Core Facility in 2012.Till date, He have published 217 full-length papers and edited 3 books; received 25 national and international research awards,executed 51 funded research grants, and refereed 81 research projects submitted for funding to national and international institutions. Member of the editorial board of two international journals, member of 11 Scientific Societies, supervised 28 graduate thesis, invited speaker in 62 scientific conferences and chaired scientific sessions in 15 conferences. In the recent years, the focus of my research has been molecular biology and immunology of mycobacterial diseases.

Kaushal Research Interest includes Tuberculosis, Allergy, Infectious Diseases, and Microarrays.

Massimo Cecaro after completing the high school in humanistic studies, he moved to the University of Camerino, where he got a Master Degree in Veterinary Medicine and in University of Teramo he successfully got the Specialization. Since the age of 14, he has worked as radio speaker, tv presenter and reporter for a wide range of artistic and scientific events. At the age of 24 he obtained a qualification to practice as a Journalist and in 2007 he was admitted to the National Association of Medical Press (ASMI), where he currently hold the position of National Councilor. He is Resident Member of MJA Medical Journalists’ Association (London). He is Member of EFSA's Expert Database. He has been an invited speaker,mentor and chairman at International events in the field of Public Health and Safety in Canada, US, Europe and Asia. He has been author of several scientific works in public health. He is also director in Italy of a prestigious Educational Centre for work safety and public health. He is actively involved in international projects to improve the role of mass-media in medical sciences, and awarded in Philadelphia, Valencia and Las Vegas with International special recognition. He is serving as an editorial member of several reputed journals like: “Journal Food Processing Technology”, “Journal of Veterinary Science & Technology”, and Editor in Chief in the “Occupational Medicine & Health Affairs” and in “Journal of Mass Communication”. He is Reviewer for "Journal od Cancer Science & Therapy”. He is Organizing Commette Member of several International Conferences in US and in Europe.

Michael Y. Galperin has received his PhD at the Lomonosov Moscow State University in Russia and postdoctoral training at the University of Louisville and University of Connecticut. He has been at the NCBI Computational Biology Branch since 1996, first as a GenBank Fellow, then Staff Scientist, and currently as a Lead Scientist. He has published more than 170research papers, reviews and book chapters and is an author of a textbook on comparative genomics. He serves as the editor of the Nucleic Acids Research annual Database Issue and editor of the Genomics Updates section in Environmental Microbiology.

Microbial genomics, particularly, reconstruction of biochemical pathways in poorly characterized organisms; COG database.

Chang received his B.S. in 1965 from the National Taiwan University, Taipei, Taiwan, a M.A. in 1968 and Ph.D. in 1972 in Cell Biology from the University of Guelph, Ontario, Canada. He was a Postdoctoral Fellow in Parasitology at Rockefeller University in New York, NY from 1972 to 1974. He held the position of Research Associate from 1974 through 1976, Assistant Professor from 1976 to 1979, and Associate Professor from 1979 through 1983 at Rockefeller University. He joined the faculty at the current university in 1983 as Professor of Microbiology and Immunology.

Gregory A. Buck earned a Ph.D. in the Department of Microbiology and Immunology at the University of Washington in Seattle, and completed his postdoctoral training in molecular parasitology at the Institut Pasteur in Paris. He is director of the Center for the Study of Biological Complexity at VCU, which includes the University’s Genomics, Bioinformatics and High Performance Computing Cores. His current research focuses on microbial and parasite genomics and metagenomics. He has published over 100 papers and chapters in reputed journals and books

Microbial and parasite genomics and Metagenomics.

Menachem Shoham completed his Ph.D in the Weizmann Institute of Science (isreal) and he is currently working in the Case Western Reserve University as an associate professor in the department of Molecular Biophysics and Biochemistry and his main research in the laboratory focuses on drug discovery and drug screening to combat infectious diseases. Shoham received many positions and honors and successfully published 57 peer reviewed publications in his research.

Akira Kaji has completed his Ph.D in 1958 at The Johns Hopkins University and did postdoctoral studies from various places including the Rockefeller Institute in New York. He is a professor of Microbiology at Univ. of Pennsylvania. He has published more than 200 papers in reputed journals.

Cory M. Robinson completed his Ph.D in Microbiology from Miami University in 2004. This was followed by postdoctoral studies at the Uniformed Services University of the Health Sciences under the direction of Dr. Alison O’Brien and at the University of Pittsburgh School of Medicine under the direction of Jerry Nau. He is currently an Assistant Professor at the University of South Carolina School of Medicine.

Timms is Professor of Microbiology and Director of Research at QUT’s Institute of Health and Biomedical Innovation in Brisbane Australia. He is a nationally and internationally renowned microbiologist with specific expertise in the area of Chlamydia. His laboratory is acknowledged as the leading Australian laboratory and one of the leading groups internationally working on all aspects of chlamydial infections. Timms has published over 170 refereed journal papers and is editor of the journal, Pathogens and Disease

Jong Hyun Ham earned his Bachelor’s degree in agricultural biology and Master’s degree in plant pathology from Korea University in Seoul, Korea. He completed his PhD in plant pathology at Cornell University in 1999. He then worked at University of Illinois at Urbana Champaign, University of Wisconsin-Madison and Ohio State University as a post-doctoral fellow and research scientist. He joined Louisiana State University Agricultural Center in 2007 as a faculty member and has worked on molecular genetics and genomics of plant pathogenic bacteria and plant-bacterial interactions at the same position.

Zhan’s primary research interest is to understand microbiological aspects of dental caries and identify protocols that will lead to prevention or elimination of dental caries in children. One of her research focus is on virulence factors of mutans streptococci and other caries-causing bacteria that are related to their transmission or initiation of dental decay. The overall goal of these studies is to identify specific genes in MS that are related to development of dental caries in children and investigate whether these genes can be used to screen children with high risk for antimicrobial treatment and also to develop targeted antimicrobial agent for caries prevention in children. The other aspect of her research is focused on seeking clinical regimens in caries prevention. She has conducted randomized clinical trails to identify effective practical antimicrobial regimens, such as povidone iodine and xylitol products, which may alter caries-causing bacteria challenge and prevent new caries in children. The third aspect oh her research is to study and develop an effective and practical Caries Management by Risk Assessment protocol (CAMBRA) for children. She is also interested in global oral health projects and recently engaged study on investigating the feasibility and efficacy of incorporating oral health education and fluoride varnish program through pediatric immunization clinic in Roatan, Honduras with a joint effort of a multidisciplinary team from UCSF and UC Berkley.

Wanda C. Reygaert is an Associate Professor of Microbiology and Immunology in the Biomedical Sciences Department at Oakland University William Beaumont School of Medicine. Dr. Reygaert earned her B.S. in Biology/Medical Technology from Indiana University, an M.S. in Biology/Microbiology from Purdue University, and a Ph.D. in Molecular Biology from the University of Illinois at Chicago. She has been a member of the American Society for Clinical Pathology (ASCP) since 1993, and a member of the American Society for Microbiology (ASM) since 1999. Dr. Reygaert joined the OUWBSOM as a founding faculty member in the Fall of 2009.

B. Y. Chin attended the United World College of South East Asia Singapore and Lawrence Academy in Groton Massachusetts high school Mount Holyoke College in South Hadley MA, BA Biological Sciences, The Johns Hopkins University ScM Physiology and PhD Toxicological Sciences. She spent her postdoctoral fellowship in Molecular Toxicology at US Department of Energy at Pacific Northwest National Laboratory in Richland WA. Currently she is at Beth Israel Deaconess Medical Center/Harvard School of Medicine in Boston MA in the Department of Surgery B. Y. Chin is also a member of the Teaching Faculty of the 1st year medical curriculum Anatomy Histology and Physiology at Harvard Medical School. She has published over 30 peer review articles and serves on the Editorial Board of World Journal of Pharmacology and as a guest editor in Current Chemical Biology.

Mohamed K. Fakhr, is currently an Assistant Professor of Molecular Microbiology in the Department of Biological Science at the University of Tulsa, USA. After obtaining his Ph.D. from Oklahoma State University in 2002, Dr. Fakhr, moved to North Dakota State University where he worked as a Postdoctoral Research Associate then a Research Assistant Professor at the Department of Veterinary and Microbiological Sciences. In 2008, Dr. Fakhr moved to Tulsa, where he currently runs an active research program in the area of Molecular Typing and Detection of Foodborne Bacterial Pathogens alongside exploring the mechanisms by which these foodborne pathogens develop resistance to antimicrobials.

Rahul Saxena received his Ph.D. in Biochemistry from the Institute of Microbial Technology, India in 2007, where he made important contributions on the structural-functional characterization of peptide deformylase (PDF), an enzyme involved in post-translational modification of proteins in the pathogenic organism Mycobacterium tuberculosis. He pursued postdoctoral studies at Georgetown University School of Medicine where his research has focused on understanding the role of acidic phospholipids present in the bacterial cell membrane in controlling chromosomal replication spatially and temporarily. Recently he was appointed to the faculty in the Department of Biochemistry and Molecular & Cellular Biology at Georgetown University Medical Center. His findings have been published in several peer-reviewed journals, as well as a portion of his work has been accepted to grant a US patent.

Akira Kaji is a professor of microbiology, School of Medicine, University of Pennsylvania. He contributed to the deciphering of genetic code by his discovery of the fact that the complex of poly-U with ribosome binds specifically tRNA specific for phenylalanine. He also discovered RRF

The following is a short review of Akira Kaji past work. In 1963, they discovered that specific tRNA binds to the complex of mRNA and ribosome. This finding was essential to decipher the genetic code (9). Regarding RRF, upon in vivo inactivation of RRF, the ribosome starts the unscheduled translation downstream from the termination codon. Crystal structure by X-ray crystallography as well as solution structure by NMR has revealed that RRF is a near perfect structural mimic of tRNA. Indeed, we found that RRF functionally mimics tRNA in that it moves in the inter-subunits space like tRNA does. However, the mode of RRF binding to the ribosome is different from that of tRNA. We also discovered arginyl-tRNA protein transferase in 1963(10). This enzyme is an essential for higher eukaryotes and involved in post-translational protein modification

Liaqat Ali Chaudhry completed MBBS from King Edward Medical College university Lahore1981. He completed his post-graduation in Diploma in Tuberculosis & Chest Diseases -Punjab University Lahore-Pakistan, MCPS from College of Physicians and Surgeons Pakistan and MRCP, FRCP from The Royal College of Physicians Dublin-Ireland. He worked as house physician, Registrar, Assistant professor at King Edward Medical College Lahore, 1982-1987. Later he joined MOH of Saudi Arabia worked as Specialist Physicians chest specialist on Feb-1988, Consultant Pulmonologist and Chief of Tuberculosis Center, Dept. of Internal Medicine & Chest diseases Dammam medical complex and Honorary Associate & Professor Dammam Medical University, Eastern Province K. Saudi Arabia – 2011 and Chairman Internal Medicine & Consultant Invasive.

Consultant Pulmonologist and Chief of Tuberculosis Center, Deptt.of Internal Medicine & Chest diseases Dammam medical complex and Honorary Associate & Professor Dammam Medical University, Eastern Province K.Saudi Arabia

Prof. Ahmed has completed his PhD from Keele University, UK, on 2002 and has ongoing Research Fellowship at Keele from 2004 until now, and Fellow of the Roial Society, UK, in 2004. He is a Professor of Medical Entomology at Zoology Department at El-Minia University, Egypt, (currently at King Saud University, Saudi Arabia). His current research interest is “mosquito immunity and biocontrol”, aiming at utilizing the immune response of mosquito vectors against mosquito-borne disease agents, and biological agents in the biocontrol measures against mosquito vectors. He has successfully achieved several grants for research projects, and got two currently ongoing granted projected (1.6 million Saudi Riyals each). One grant is for isolating native mosquito Bacillus thuringiensis bacteria with enhanced larvicidal activities for use in the battle against mosquito vectors in Saudi Arabia. The other grant is for isolating immune peptides from honey-bees for use as natural antibiotic against the American Foal Broad disease (AFB) that threatens the global Apiary industry. He had successfully monitored undergraduate, postgraduate students and research scholars. His academic output consists of more than 26 papers in reputed journals, membership of several Scientific societies, attended several local, national & international conferences and invited for main talks in many international conferences.

Professor of Medical Entomology at Zoology Department at El-Minia University

Professor George L. Mendz has an MSc from the University of Barcelona (Spain), and a PhD from the University of NSW. He has been Lecturer at the College of Natural Sciences, the University of Puerto Rico (San Juan); Research Associate at the School of Chemistry and the Department of Biochemistry, the University of Sydney; ARC Senior Research Fellow and Associate Professor at the School of Biochemistry and Molecular Genetics, the University of NSW; Associate Professor at the Department of Bacteriology, the University of Bordeaux II; and Associate Professor at the School of Medical Sciences, the University of NSW.

More recently, he had acquired expertise in global analyses involving proteomics and transcriptomics by investigating microorganism responses to stress, as well as in bacterial genome sequencing and the application of metagenomics to characterise bacterial populations.

1996-present: Director, WM Keck Center for Transgene Research, University of Notre Dame. 1983-present: Kleiderer/Pezold Professor of Biochemistry, University of Notre Dame. 1979-2002: Dean, College of Science, University of Notre Dame. 1977-1983: Professor, University of Notre Dame. 1974-1977: Associate Professor, University of Notre Dame. 1970-1974: Assistant Professor, University of Notre Dame. 1968-1970: NIH Postdoctoral Fellow, Duke University. 1968: Ph.D. in Biochemistry, University of Iowa. 1964: B.S. University of Scranton. 2006-present: Adjunct Professor of Biochemistry & Molecular Biology, Indiana University School of Medicine.

The interests of Professor Castellino\'s laboratory involve the structure, function and activation of proteins that participate in blood coagulation and blood clot dissolution. The in vivo mechanisms of the roles of these proteins in these processes are being addressed through in vivo targeted gene-replacement approaches and corresponding in vitro structure-function studies on these genes and proteins are being studied by the most modern biophysical techniques, e.g., X-ray crystallography, NMR, etc. Most of these proteins exist in an inactive state in plasma and thus must be activated to enzymes to exhibit their functional properties. The molecular events involved in the activation and analysis of the concomitant structural changes that occur in the protein are investigated by modern biochemical techniques. Major tools of the laboratory involve cloning, mutagenesis and expression of variant recombinant proteins and individual protein domains, immunochemical studies of the proteins, as well as physical and chemical analysis of their solution structures. The properties of the proteins are then related to their functions. Another project receiving attention involves the structure-function relationships of small gamma-carboxyglutamic acid (Gla)-containing peptides from marine cone snails that target the brain NMDA receptor. These peptides inhibit the flow of calcium into neuronal cells, this latter event being responsible for the neuropathology associated with stroke, epilepsy, Alzheimer\'s Disease, ALS, etc. The biochemical, pharmacological and neurobiological mechanisms of the actions of these peptides are under study. Peptide synthesis, receptor binding, molecular biological and electrophysiological tools are currently employed in this work. To determine the biological functions of genes encoding coagulation and clot-dissolving proteins in hemostasis, cancer, inflammation, wound healing, embryonic implantation and development, metastases, and athersclerosis, gene deletion and other gene targeting experiments are being performed in mice, in conjunction with phenotyping of these animals. Such studies are expected to provide important information on the development and progression of these disease states.

Dr. Joshi is director of center for surgical infections and biofilms. He is an associate professor in the Departments of Microbiology & Immunology and Dermatology, and Surgery, and an adjunct professor at the A.J. Drexel Plasma Institute, as well as Drexel's School of Biomedical Engineering. He has a special interest in emerging bacterial infections, novel disinfection and sterilization techniques, and biodefense bacterial vaccines. Since 1987, Dr. Joshi has taught undergraduate, postgraduate and doctoral students, and trained doctoral and postdoctoral, residents and fellows for research. He has been mentoring graduates and medical students, who now have successful careers in medicine, academia and the pharmaceutical industry. Since 2004, he has been a member of international mentoring program and minority mentoring program of American Society of Microbiology (ASM), and Infectious Disease Society of America (IDSA). He is physician-researcher-teacher, and eligible member of American Board of Medical Microbiology.

Emerging bacterial infections, host-pathogen interactions, hospital-acquired infections, antimicrobial drug resistance, novel infection control strategies, carbapenem-resistant Acinetobacter baumannii, botulism & bacterial biofilms

Dr. Ananda M. Chakrabarty serves as Senior Science Advisor of Amrita Therapeutics Limited. Dr. Chakrabarty is a Amrita’s Senior Science Mentor and Global Domain Expert relating to how bacterial proteins effectively combat cancers, parasites, and viruses in the human body. Dr. Chakrabarty serves as a Distinguished University Professor of Microbiology and Immunology at the University of Illinois College of Medicine, and advises senior officials in the U.S. and abroad on policies relating to biotechnology and related technology transfer. He is a Consultant to the United Nations. In 1980, Dr. Chakrabarty’s genetically modified Pseudomonas bacteria became the first genetically-engineered organism to gain a patent, as a result of the Supreme Court decision in Diamond vs. Chakrabarty. Dr. Chakrabarty undertook pioneering biotechnology research into the therapeutic potential for protein products of bacteria, both at the University of Illinois at Chicago (UIC) and on behalf of CDG Therapeutics, a U.S. biotechnology start-up company engaged in clinical cancer research. Dr. Chakrabarty has led path-breaking research into the therapeutic qualities of protein products of bacteria. His work includes recent studies with water-soluble products of pathogenic bacteria demonstrating significant promise for cancer therapies, effective against HIV/AIDS, malaria and perhaps even tuberculosis. Dr. Chakrabarty was a part of the Advisory Committee that resulted in creation of the International Center for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy and rejoined the ICGEB Advisory Board. Dr. Chakrabarty has numerous publications and has received many notable awards for his contributions to biotechnology, including Padma Shri in 2007, one of the Indian Government’s highest civilian honors.

Cell Biology, Microbiology, Pseudomonas aeruginosa, Cancer Cells, Biotechnology, Oncology, Cancer Biology, Cancer Therapy, Pseudomonas, Malaria, Cystic Fibrosis, Genetic Engineering, Infectious Diseases, Cancer Chemotherapy, Mutation

Akira Kaji is a professor of microbiology, School of Medicine, University of Pennsylvania. He contributed to the deciphering of genetic code by his discovery of the fact that the complex of poly-U with ribosome binds specifically tRNA specific for phenylalanine. He also discovered RRF.

The following is a short review of Akira Kaji past work. In 1963, they discovered that specific tRNA binds to the complex of mRNA and ribosome. This finding was essential to decipher the genetic code (9). Regarding RRF, upon in vivo inactivation of RRF, the ribosome starts the unscheduled translation downstream from the termination codon. Crystal structure by X-ray crystallography as well as solution structure by NMR has revealed that RRF is a near perfect structural mimic of tRNA. Indeed, we found that RRF functionally mimics tRNA in that it moves in the inter-subunits space like tRNA does. However, the mode of RRF binding to the ribosome is different from that of tRNA. We also discovered arginyl-tRNA protein transferase in 1963(10). This enzyme is an essential for higher eukaryotes and involved in post-translational protein modification.

Awards RESEARCH & SCHOLARSHIP AWARDS 2015 Fellow of the American Academy of Microbiology 2014 Faculty Excellence Award (one award given per year within the School of Molecular and Cellular Biology at the University of Illinois). 2004 Award for Excellence in Research and Scholarship at the Associate Professor Level - University of Houston (one university award per year at each academic rank). 2002 Award for Excellence in Research and Scholarship at the Assistant Professor Level - University of Houston (one university award per year at each academic rank).  1999 Young Investigator Award, 10th International Meeting Campylobacter & Helicobacter. 1997 Natural Science and Mathematics Alumni Association Award. 1996 Oakridge Junior Faculty Award for Life Sciences Research. 1981 NSF Undergraduate Research Award. TEACHING AWARDS AND RECOGNITION 2010, 2013 Cited as a Teacher ranked as outstanding by their students for Molecular and Cellular Biology/Life Sciences and College of Medicine Courses. 2008, 2009 Cited as a Teacher ranked as excellent by their students for Molecular and 2011, 2012 Cellular Biology/Life Sciences and College of Medicine Courses. 1999 Teaching Excellence Award, College of Natural Sciences and Mathematics. 1998-1999 University of Houston Enron Award for Excellence in Teaching at the University level. RECENT LECTURESHIPS, MEETING CHAIRS, LEADERSHIP POSITIONS 2015 Vice-Chair, Gordon Conference on Chemical & Biological Terrorism Defense, Ventura, CA, March 2015. 2013 Chair, Bacteria-Host Interactions (2013) 2013 International Conference on Bacillus anthracis, B. cereus, and B. thuringiensis, Victoria, Canada, September 2, 2013. 2013-2014 Chair, Division B (Microbial Pathogens) of ASM. 2013 Discussion Leader/Session Chair, Organizing Committee, 2013 Gordon Conference on Chemical & Biological Terrorism Defense, Ventura, CA, March 10-15, 2013. 2012-2013 Chair Elect, Division B (Microbial Pathogens) of ASM, 2012-2013. 2011 Session Chair, Organizing Committee, 2011 International Conference on Campylobacter, Helicobacter, and Related Organisms, Vancouver, British Columbia, Canada, August 28 – September 1, 2011. 2011 Keynote Speaker, 23rd Annual Buffalo Conference on Microbial Pathogenesis – Witebsky Center for Microbial Pathogenesis and Immunology (2011) Of Persistence, Cancer, and Asthma: The Curious Case of Helicobacter pylori, Buffalo, NY, April 29, 2011. 2011 Organizing Committee, and Discussion Leader/Session Chair, 2011 Gordon Conference on Chemical & Biological Terrorism Defense, Ventura, CA, March 20-25, 2011.

Genetics, Host-Pathogen Interactions, Membrane Biology, Microbial Physiology, Molecular Immunology, Receptor Biochemistry, Signal Transduction, Toxins

Dr. Kei Amemiya is a Principal Investigator in the Bacteriology Division at the US Army Medical Reseach Institute of Infectious Diseases. He has been at USAMRIID since 1999 and has been involved in developing vaccine candidates against plague, glanders, and melioidosis. His interest has been in studying the host’s immune response to the pathogen and vaccines in small and large animal models. Before coming to USAMRIID, he was at the National Institutes of Health and Georgetown University, where he was studying the host response to bacterial and viral pathogens or autoimmune diseases in humans.

Molecular Biology, Immunology, Microbiology, Infectious Diseases

Dr. Goc obtained her M.S. and Ph.D. from the Jagiellonian University, Cracow, Poland. She conducted her postdoctoral training at Case Western Reserve University, Cleveland, OH, and the University of Georgia, Athens, GA. She also worked as a Research Biologist at the VA Medical Center, Augusta, GA. Currently, as a Head of Infectious Diseases Division at Dr. Rath Research Institute, Santa Clara CA, she leads a Lyme disease project. Dr. Goc has published over 30 peer-reviewed publications, two book chapters, and has presented her research at numerous national and international scientific meetings. She is also an active member on one editorial board and the recipient of several national and international awards.

Molecular biology, biochemistry and cell biology in the fields of microbiology, immunology, cancer, and vascular biology

Wanda C. Reygaert is an Associate Professor of Microbiology and Immunology in the Biomedical Sciences Department at Oakland University William Beaumont School of Medicine. Dr. Reygaert earned her B.S. in Biology/Medical Technology from Indiana University, an M.S. in Biology/Microbiology from Purdue University, and a Ph.D. in Molecular Biology from the University of Illinois at Chicago. She has been a member of the American Society for Clinical Pathology (ASCP) since 1993, and a member of the American Society for Microbiology (ASM) since 1999. Dr. Reygaert joined the OUWBSOM as a founding faculty member in the Fall of 2009.

Biology/Microbiology, Clinical Pathology

Mohamed K. Fakhr, is currently an Associate Professor of Molecular Microbiology in the Department of Biological Science at the University of Tulsa, USA. After obtaining his Ph.D. from Oklahoma State University in 2002, Dr. Fakhr, moved to North Dakota State University where he worked as a Postdoctoral Research Associate then a Research Assistant Professor at the Department of Veterinary and Microbiological Sciences. In 2008, Dr. Fakhr moved to Tulsa, where he currently runs an active research program in the area of Molecular Typing and Detection of Foodborne Bacterial Pathogens alongside exploring the mechanisms by which these foodborne pathogens develop resistance to antimicrobials.

Microbiology, Biological Science, Veterinary Science

Dr. Ling Zhan is a pediatric dentist and professor who cares for children and adolescents at both the Mission Bay and Parnassus campuses. Her treatment philosophy is very prevention-oriented. She works closely with her patients and their families to identify risk factors for common dental diseases, such as dental caries, and to adopt scientifically-based preventive and treatment regimens to avoid future diseases. Her practice provides routine as well as complex care, including care for children with dental or medical conditions who require treatment under sedation or general anesthesia. She works closely with other dental specialties to treat children with complex dental disease, such as amenogenesis imperfecta. In addition to patient care and education, Zhan conducts clinical and translational research projects that are focused on microbiological aspects of tooth decay; oral prevention programs guided by risk assessment; and identification of protocols to prevent or eliminate dental caries in children. Zhan completed her pediatric dentistry residency training at UCSF. She is a member of the American Academy of Pediatric Dentistry and a diplomate of the American Board of Pediatric Dentistry.

Pediatric Dentistry, microbiological aspects of tooth decay, dental diseases

Timms is Professor of Microbiology and Director of Research at QUT’s Institute of Health and Biomedical Innovation in Brisbane Australia. He is a nationally and internationally renowned microbiologist with specific expertise in the area of Chlamydia. His laboratory is acknowledged as the leading Australian laboratory and one of the leading groups internationally working on all aspects of chlamydial infections. Timms has published over 170 refereed journal papers and is editor of the journal, Pathogens and Disease.

He leads a well established research team of 10 people. His research group is developing vaccines and new diagnostics for chlamydial diseases in humans and animals as well as an improved understanding of chlamydial genomics, cell biology and pathogenicity. The group is widely acknowledged for its major contributions to chlamydial infections in koalas and other wildlife, including the development of a vaccine for koalas.

Liaqat Ali Chaudhry completed MBBS from King Edward Medical College university Lahore1981. He completed his post-graduation in Diploma in Tuberculosis & Chest Diseases -Punjab University Lahore-Pakistan, MCPS from College of Physicians and Surgeons Pakistan and MRCP, FRCP from The Royal College of Physicians Dublin-Ireland. He worked as house physician, Registrar, Assistant professor at King Edward Medical College Lahore, 1982-1987. Later he joined MOH of Saudi Arabia worked as Specialist Physicians chest specialist on Feb-1988, Consultant Pulmonologist and Chief of Tuberculosis Center, Dept. of Internal Medicine & Chest diseases Dammam medical complex and Honorary Associate & Professor Dammam Medical University, Eastern Province K. Saudi Arabia – 2011 and Chairman Internal Medicine & Consultant Invasive.

Consultant Pulmonologist and Chief of Tuberculosis Center, Deptt.of Internal Medicine & Chest diseases Dammam medical complex and Honorary Associate & Professor Dammam Medical University, Eastern Province K.Saudi Arabia.